(Reuters) -British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a stake sale in Haleon, bringing down its shareholding to 7.4% in the world’s largest standalone consumer healthcare firm.
The sale of 270 million shares at 328 pence apiece, represented a discount of about 2.5% to Haleon’s last close of 336.25 pence on Thursday.
GSK earlier this year sold 240 million shares in Haleon to raise about 804 million pounds ($1 billion), and lowered its stake to 10.3% from 12.9% it initially retained in the business.
Haleon was formed in 2019 through a merger of GSK and Pfizer’s consumer healthcare businesses. It was spun out and listed on the London Stock Exchange in July 2022.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Pfizer, which holds a 32% stake in Haleon, said in May it plans to cut its ownership in a “slow and methodical” manner within months.
($1 = 0.8216 pounds)
(Reporting by Prerna Bedi in Bengaluru; Editing by Sonia Cheema)
